HOLX · HOLOGIC INC
$76.01
+0.00 (+0.00%)
At close · Apr 7
Market Cap
$16.97B
Shares
223.24M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Stephen MacMillan | CEO | $15,819,261 |
| Karleen Oberton | CFO | $4,090,438 |
| Essex Mitchell | COO | $4,083,725 |
| Jan Verstreken | Group President, International | $3,585,895 |
| John M. Griffin | General Counsel | $3,474,051 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephen MacMillan | CEO | $15,555,032 |
| Karleen Oberton | CFO | $3,934,620 |
| Jan Verstreken | Group President, International | $3,523,984 |
| John M. Griffin | General Counsel | $3,341,111 |
| Kevin R. Thornal | Former Group President, Global Diagnostic Solutions | $2,728,293 |
| Essex Mitchell | COO | $2,172,586 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stephen P. MacMillan Chairman | CEO | $14,335,632 |
| Stephen MacMillan | CEO | $14,335,632 |
| Karleen Oberton | CFO | $3,597,619 |
| Kevin R. Thornal | Former Group President, Global Diagnostic Solutions | $3,324,873 |
| John M. Griffin | General Counsel | $3,242,089 |
| Jan Verstreken | Group President, International | $2,753,419 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stephen MacMillan | CEO | $14,748,400 |
| Stephen P. MacMillan Chairman | CEO | $14,748,400 |
| Karleen Oberton | CFO | $3,568,125 |
| John M. Griffin | General Counsel | $3,314,127 |
| Kevin R. Thornal | Former Group President, Global Diagnostic Solutions | $3,112,390 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Stephen P. MacMillan Chairman | CEO | $14,125,674 |
| Karleen Oberton | CFO | $3,137,407 |
| John M. Griffin | General Counsel | $2,965,305 |
| Kevin R. Thornal | Former Group President, Global Diagnostic Solutions | $2,873,486 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Stephen MacMillan | CEO | $12,374,753 |
| John M. Griffin | General Counsel | $2,623,024 |
| Peter J. Valenti | Former Division President, Breast and Skeletal Health | $2,590,327 |
| Karleen Oberton | CFO | $2,457,965 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stephen MacMillan | CEO | $42,040,142 |
| General Counsel | — | $2,432,914 |
| Peter J. Valenti | Former Division President, Breast and Skeletal Health | $2,037,538 |
| Karleen Oberton | CFO | $1,139,643 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Stephen MacMillan | CEO | $11,204,908 |
| General Counsel | — | $2,351,217 |
| Peter J. Valenti | Former Division President, Breast and Skeletal Health | $2,319,159 |